Member Info for LordTopUp

There appears to be 10 bad reviews for every 1 good one, so if that translates into repeat sales, then new sales would have to increase 10 fold on a consistent basis to compensate for lost repeat sales. Yesterday's RNS was therefore necessary despite all the ridiculous conspiracy theories on here. A very very deep hole here which I can't see anyway out.

Lord

Didn't Haleon say their sales target is $100 million a year? So if a unit sells at $20 (net of VAT) then that works out they need to sell over 400,000 units a month (= $8 million) to achieve their target. so 20k on Amazon (which I'm guessing is the biggest seller) is pathetic and it's no wonder milestones are being missed. Train crash coming here.

Lord

This could get very messy. We're not just talking about a slight reduction in predicted sales, but a huge 50% reduction. You can assume that eroxon will have been stock piled in anticipation for much larger sales volumes so there's now probably stacks of unsold stuff on shelves and in the warehouse with a finite expiry date. So possibly a huge stockpile sell off at a loss but also the need for expensive advertising to even sell at reduced prices. Very messy indeed.

Lord

You got personal, dosanddonts. The irony re your new thread header is that you were attacking (in a personal way) my own right to free speech.

I've warned all along this would happen. The reviews on Amazon USA are really bad from verified buyers (even though the rampers claimed them as fake, or that only angry buyers gave reviews, even though there are thousands of over 4 star other product reviews).

Barder has been criticised as being incompetent but he's played a blinder. FUM has been listed for over 20 years and he's been paid millions in remuneration and never repaid a single penny dividend to all those "investors" who paid his remuneration. I remember a few years back when the BOD boasted about using their own money to take part in a placing, but when you read the year end accounts a few months later they had paid themselves big bonuses to cover the share purchase. Typical AIM gravy train.

Today's RNS is a shocker and if you read it closely it gets worse. For example:

"Whilst Eroxon is now available in many major markets across Europe and the UK, the timing of further launches within the EU have been slower than originally anticipated and we are working closely with our commercial partner Cooper Consumer Healthcare in accordance with our commercial agreement to address these issues and gain greater visibility around the challenges Cooper faces in generating greater consumer awareness in the potential target market for Eroxon. "

..... in accordance with our commercial agreement? What does that mean? Coopers no longer playing ball by pulling expensive advertising and FUM have to enforce the agreement?

The devil is in the detail. I was right about the SP being on a cliff edge and I predict this will be sub 10p by results day after which it will get a further smashing.

Lord

The chart is not looking good. If this breaks below 30p then looks like a very sharp drop towards 20p

Lord

The relatively short period between USA launch and Fum's year end may just about mask the likelihood of a huge decline in sales due to lack of repeat purchases judging by the really bad "verified" reviews on Amazon USA. The monthly sales on Amazon UK appear to have already fallen off a cliff to 100 a month from a peak of 7k a month. Then just checked the Boots website which said just 29 purchased in the last 24 hours. Looks like a disaster in the making IMO.

Lord

The reviews on Amazon USA are getting more aggressive with the latest threatening to start a lawsuit .......

https://www.amazon.com/Eroxon-Erectile-Dysfunction-Treatment-Clinically/dp/B0DBWQH8N1/ref=zg_bs_g_10786421_d_sccl_10/131-0936804-5607224?psc=1

Even the most blinkered FUM shareholder must be getting quite concerned about how badly received eroxon is in the States. They love going to court over there, most of their dramas are set in the court room!

Lord

Head in the sand, and typical ramping response. There's only so much you can say about a product so you're bound to get "similar" narratives. The proof is there - many different "verified purchases". Also America is the land of litigation. Ask GSK.

Only 2 weeks into the US launch and already it looks really bad. How long before a journo jumps on?

Lord

Doesn't appear to say. On Amazon UK it started off at over 7k a month but fell to less than 1k. Cannot seem to find eroxon on Amazon UK at the moment for some reason. Falling sales and the risk of claims is a huge concern.

Lord

Https://www.amazon.com/Eroxon-Erectile-Dysfunction-Treatment-Clinically/dp/B0DBWQH8N1/ref=zg_bs_g_10786421_d_sccl_10/131-0936804-5607224?psc=1

Lord

The reviews on the American Amazon website are appalling - over 80% one star reviews from verified purchases. And before some say disgruntled customers are more likely to give reviews, that's nonsense. I buy loads of stuff on Amazon which have excellent overall reviews. And some of the customers appear very angry, claiming eroxon to be a scam with no active ingredients. Is a can of worms about to be opened?

Lord

Will the $5 million milestone receipt be used to pay shareholders a dividend or the directors fat bonuses? Discuss

Lord

A very thought provoking point for discussion, bald eagle.

In my view, FUM are "all over the place" and don't really know what they're doing to be honest. For all their efforts to sell the (as yet) unpatented placebo, there are still no takers as FUM now appears to be permanently re-rated as a penny share.

A very badly run company trying to peddle junk sums FUM up for me.

Enjoy the sunshine this weekend but remember not to break the lockdown rules. Fortunately Lady Top Up and I have the luxury of ab extremely large garden.

Toodle pip!

It's all smoke and mirrors, bald eagle.

The very purpose of FUM becoming listed was to complete CSD AFTER the deal with SSL so it could raise the necessary capital and become a sleeping partner receiving royalty income.

Once CSD was returned and it was obvious it would then fail, MED "conveniently" became a valuable asset despite having been returned by both RB and GSK. They apparently looked at it and thought it was rubbish. Just like all the "potential partners" in commercial discussions. Nobody was interested and they were proved right as MED failed Phase 3.

Now it's groundhog day all over again as it's rinse and repeat time with MED3000. Again nobody is interested - it's a pile of junk only bigged up by FUM's own very well paid directors. Hmmmmm, I wonder why! The phrase "a fool and his money are easily parted" should be put forward as a prime example for FUM shareholders. Just saying!

Sad to see them losing money like this, but I suppose they deserve it as they've already been stung by the previous MED. Again another phrase springs to mind: "Fool me once, shame on you. Fool me twice, shame on me".

Enjoy the weekend each and every one and TOODLE PIP!

He did seem to be grinning rather than smiling! I thought he looked quite well for someone over 60, but that's probably because he's never done a days work in his life. Lady Top Up thinks he either wears a wig or dyes his hair! She may have a point!

A very warm welcome, hawkhead, I trust you are well.

I totally agree with your assessment that Viagra is too strong to compete against. Bald eagle brought up the issue of CSD disappearing, and that was down to Durex being too strong so once Reckitt returned the rights (what's the point in eating into their own dominant market share?) and Church & Dwight the clear 2nd best chickening out, CSD was never going to succeed.

Exactly the same is happening with the (as yet) unpatented placebo. Nobody has the clout to compete with Viagra so it will end up in the same waste bin as CSD. That belief is backed up with no commercial deals.

Enjoy the rest of your evening and remember to applaud our brilliant NHS staff cometh the hour.

Does anybody believe a word that comes out of Barder's mouth?

Excellent post, bald eagle. A very fair and honest assessment as to where we're at with FUM.

One thing which did make me laugh was a claim by donkeykong that a "subject to" deal may have been signed. What utter nonsense. It's blatant ramping like this which should be stopped. Quite sad, really, that some post such tripe. But I suppose things are getting desperate! Small sells now knocking this down, not looking good.

Just checking the TPR section on FUM's website:

"This work is progressing, and we expect Thornton & Ross to respond by the end of February 2020 within the timelines agreed with the MHRA."

You have got to laugh!

Toodle pip!

Good evening. ladies and gentlemen.

Firstly may I commend bald eagle's posts in the face of extreme adversity, some may even say "cyber bullying". I know many on here are well down due to averaging down from the 40s, but there's no need for the aggressive behaviour displayed.

Now to my thread header "financial tightrope". There's been some alarming (embarrassing even) ignorance shown regarding the understanding of FUM's finances. Several have pointed to the post year end cash "injection" re the tax credit. No no no! That's included in the year end balance sheet which contributes to covering the trade payables of nearly £5 million so is "already spoken for".

In fact, FUM had net current liabilities at 31/12/19 with the tax credits to be received plus the cash balance falling short of what was owed. The post year end fund raise of £3 million quite literally saved FUM from bankruptcy just in the nick of time - close shave, guys!

I thank the lord (not me, the great man in the sky!) that I'm not invested here. It seems quite obvious this is just being strung out further like it has been for the past 17 years, but hats off to FUM, they continue to sucker in their "loyal band" of shareholders, even though some may argue that they're trapped.

But I will continue to observe and contribute as always. I've got my answer re TPR. I knew it had hit the buffers, I did tell you all! They still haven't updated their website, however:

"This work is progressing, and we expect Thornton & Ross to respond by the end of February 2020 within the timelines agreed with the MHRA."

What a professional bunch of folk …….. NOT!

The very very best of luck and do enjoy the rest of your evenings.

Toodle pip!